Recombination in HIV: an important viral evolutionary strategy. by Burke, D. S.
253 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
Perspectives
Human immunodeficiency virus (HIV)-1, like
all retroviruses, is “diploid.” Each viral particle
contains two RNA strands of positive polarity,
each full length and potentially able to replicate
(1). No other virus families, RNA or DNA, are
diploid. Typically both RNA strands in a retro-
viral particle derive from the same parent
provirus. However, if an infected cell simul-
taneously harbors two different proviruses, one
RNA transcript from each provirus can be encap-
sidated into a single “heterozygous” virion. When
this virion subsequently infects a new cell, the
reverse transcriptase may jump back and forth
between the two RNA templates so that the
newly synthesized retroviral DNA sequence is
recombinant between that of the two parents (2).
All subsequent progeny virions will be of this
recombinant genotype. HIV-1 strains with chimeric
genomes thought to have arisen through
homologous recombination have recently been
discovered in nature (3).
Temin observed that the replication strategy
of HIV-1 suggests a form of primitive sexual
reproduction (4), which is apparently genderless
but sexual in that 1) two parental gametes must
fuse into a single progeny, 2) the genetic
information of the parental strains is recombined,
and 3) subsequent offspring carry genetic
information from both parents.
Theoretical Advantages and
Disadvantages of Recombination
The replication error rate for HIV is such that
each newly synthesized HIV genome carries on
average approximately one mutation (5). This high
mutation rate, common to most RNA viruses,
permits rapid exploration of nucleotide sequence
space (the universe of all possible RNA sequences)
(6). Only certain regions of sequence space encode
replication-competent viruses; these regions can
be conceptualized as “peaks” on a “fitness land-
scape” of sequence space. Although a high mutation
rate can lead to rapid evolution, too high a muta-
tion rate carries the danger that the encoded
information may degenerate into gibberish. For an
organism with a very high mutation rate, an
efficient recombination mechanism provides at
least two significant theoretical advantages.
Escape from Muller’s Ratchet
(Within a Fitness Peak)
For any organism with a genome sequence
exactly on a peak on the fitness landscape, every
new mutation is by definition not beneficial.
Furthermore, unfavorable mutations accumulate
more rapidly than restorative back-mutations.
Muller showed that in the absence of recom-
bination, the net effect is an inexorable stepwise
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“ratcheting down” in fitness of the entire
population, where each step in the “ratchet”
represents loss of the previously most highly fit
genomic sequence. Genetic recombination can
readily bring about regeneration of perfectly fit
organisms from less than perfectly fit parents (7).
Evolutionary Broad Jumping
(Between Fitness Peaks)
On rugged fitness landscapes—regions of
sequence space where as few as one or two
mutations can be lethal—an organism may be
trapped on a fitness peak because locations in
sequence space near the peak may all be non-
viable. In such circumstances, step-by-step muta-
tion is not an option for exploration of sequence
space. Recombination between two such highly
niched organisms can generate progeny that may
fortuitously “land” on unexplored fitness peaks at
positions in sequence space between those of the
parents. Kaufman has dubbed this process
“evolutionary broad jumping” (8).
For conventional plus-stranded RNA viruses,
replication occurs in the cytoplasm. A plus RNA
strand growing on a negative strand template
can transiently hybridize with other template
(negative) strands to form a replication complex,
thereby confusing the polymerase into a “copy
choice” that can lead to template switching (9). In
contrast, transcription of a retroviral genomic
plus strand is restricted to a fixed location in the
nucleus where the negative strand template is
integrated into the host chromosomal DNA.
Unable to utilize the conventional “replication
complex” mechanism for recombination during
forward transcription, retroviruses may have
evolved an alternative mechanism to bring two
strands together within a single virion to permit
recombination during reverse transcription.
As for all organisms that reproduce sexually,
the cost is high: half the genetic information in
each generation is wasted. Furthermore, the
efficiency of retroviral recombination is unclear.
Many “matings” occur between sibling strands
derived from the same provirus, which may be
identical or differ at only one or two nucleotides.
At the other extreme, coinfection of a single cell
by two very different lentiviruses may not give
rise to any heterozygous virions, and even if
copackaging does occur, the degree of sequence
identity may be insufficient to permit homo-
logous recombination (10).
Evidence of HIV Recombination in Nature
In the research laboratory, recombination is
widely considered a dominant feature of retro-
viral genetics. When cell cultures are coinfected
with retroviruses that contain genetic markers at
specific sites on their genomes, recombinant
progeny arise frequently, and markers as close as
1,000 nucleotides segregate “as if unlinked” (1).
The possibility that HIV-1 strains might
recombine in nature was proposed early in the
epidemic (11). However, the first compelling evi-
dence for lentivirus recombination in nature was
the discovery that isolates from sabeus monkeys
in western Africa were chimeras between the
simian immunodeficiency virus (SIV) of African
green monkeys and the SIV of sooty mangabeys
(12). The sabeus monkey SIV was shown to be a
recombinant resulting from at least two inter-
strand crossovers between genomes of the green
monkey and mangabey viruses.
Most HIV-1 strains from around the world
can be placed into one of nine nucleotide
sequence-defined clades; these clades have been
given the letter designations A through I.
However, more than a dozen HIV-1 strains iso-
lated from patients have now been shown to have
chimeric genomes in that their gag and env
genomic regions cluster with different clades
(13). Interclade recombination is relatively easy
to demonstrate because strains from different
clades typically differ substantially in their
nucleotide sequence identities. For example, the
env gene sequences of HIV-1 strains of different
clades may differ by 20% or more (14). As might
be expected, interclade HIV-1 recombinants have
most often been detected in geographic regions
where two or more clades are prevalent (14). For
example, A clade and D clade viruses cocirculate
in East Africa, and several A/D recombinant
viruses have been detected in this region. In
western equatorial Africa, multiple HIV-1 clades
(A, C, D, E, F, G, and H) as well as the outlier
“group O” HIV-1 strains are known to cocirculate,
and preliminary studies suggest that recombinant
forms are quite common in this region. Most are
recombinants between the A clade, which is
predominant, and another clade. The rapidly
spreading HIV-1 strain in Southeast Asia is one
such recombinant, of A with E (15). This strain
consists of A clade gag and pol genes, but the env
gene is chimeric: the surface gp120 envelope
protein and external domain of transmembrane255 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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gp41 envelope protein are contributed by the E
clade, while the cytoplasmic domain of gp41 is
again A genotype. In effect, this epidemic strain
is a  pseudotyped A virus that carries an E
envelope. A wide variety of genetically similar
recombinant E/A strains have been found in
equatorial Africa, so it is likely that the recom-
binant event occurred there and a subclone was
introduced into Southeast Asia by an infected
traveler. B/F recombinants have been found in
Brazil, where both parental clades are found (16).
Intraclade recombinants are much more
difficult to detect and demonstrate convincingly
because of the genetic similarity of the parental
strains. Clones of B clade viruses from the blood
of a patient with acute retroviral syndrome who
had had multiple sex partners were found to
belong to three distinct clade B env variants (17).
Some of the clones appeared to be probable
recombinants. Strains from an infant who had
been transfused with blood from two HIV-
infected donors in 1984 were found to include
probable B intraclade recombinants (18).
Studies of specimens from an A/C-infected
spousal pair in Zambia have shown that a variety
of recombinants can be present in one small
epidemiologic cluster at different times, sug-
gesting that recombination may be continuous
and ongoing in vivo in patients who are coinfected
with two or more distinct strains (19).
Mechanisms of Retroviral Recombination
The exact mechanism by which two retroviral
RNA genome strands are copackaged into a single
virion—“mating”—is only partially understood.
A key step is thought to be the dimerization of the
two strands near their 5' genome termini (20),
which in turn permits interaction of the RNA
packaging signals with gag proteins.
Two genomes per virion is a necessary but not
sufficient condition for retroviral recombination:
the reverse transcriptase must also readily
switch strands (21). Low processivity (loose
adherence to the template RNA) is an inherent
property of retroviral reverse transcriptases. In
the normal retroviral replication cycle, the
reverse transcriptase and approximately 1,000
bp of the nascent DNA minus strand jump from
the plus RNA strand 5' repeat region to the
identical repeat region at the 3' end of the
genome. Presumably the low processivity
required to permit this jump from one end of the
genome to the other also permits ready
interstrand switching (4).
Preferred sites for HIV recombination, if any,
remain uncertain. If recombination “hot spots”
are found, they may be dictated by RNA secon-
dary structures that retard polymerase
movement, as with other viruses. Alternatively,
physical sites of recombination may be essentially
randomly distributed along the genome, and
apparent recombination hot spots might simply
reflect selection for viability.
HIV as a Primitive Sexual Organism
Once the replication of HIV is viewed as
that of a primitive sexual organism (diploid
with mating), it is instructive to reexamine the
biology of HIV for other features that might
facilitate a sexual life style.
Syncytium Induction
Some HIV strains induce formation of
multinucleated syncytia in cell cultures in vitro;
this property has been associated with clinical
virulence (22). Syncytia formation might facilitate
multiple infection of a single cell by fusing two or
more infected cells into one. Syncytium-inducing
strains may be more virulent not because syn-
cytium induction per se leads directly to
immunopathogenesis, but because this property
permits more efficient generation of rapidly
growing variants through recombination and
selection. Syncytia induction might, therefore,
represent a mechanism to optimize the spatial
interactions between strains: a mating ground.
tat/tar Transactivation
Integrated HIV provirus remains trans-
criptionally inactive unless the LTR promoter
region is activated by cellular activation factors.
HIV transcription can also be autocatalytically
increased by binding of the HIV tat protein to the
tar region of the LTR. If two different proviruses
are present in the same cell, transactivation
through tat produced by either provirus could
lead to synchronization of replication of both pro-
viruses. There is also evidence that tat can be
released from infected cells and be taken up into
and transactivate tar sequences in other infected
nearby cells (23). The tat/tar interaction might be
thought of as a pheromone, or a specific mate
recognition system that optimizes the temporal
interactions between strains.256 Emerging Infectious Diseases Vol. 3, No. 3, July–September 1997
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The Lentivirus Gene Pool and Origins of
Contemporary HIV Clades
At least 17 HIV clades have now been
reported in humans: nine HIV-1 clades in the
major grouping (A through I), three HIV-1 group
O group “outlier” clades, and five HIV-2 clades.
An additional three lentiviruses are known in
nonhuman primate species (African green
monkeys, mandrils, and Syke’s monkeys). Thus
the potential gene pool for primate lentivirus
recombination is on the order of 20, e.g., 20 gag
genes and 20 pol genes. The current HIV-1 clades
may have arisen in part through past recom-
bination between some of these genes.
Rates of transspecies infections with lenti-
viruses have not been measured. SIV has infected
persons handling SIV-infected monkeys or virus
cultures in the United States (24). Furthermore,
phylogenetic data suggest that the human HIV-2
virus is almost certainly derived from SIV of
sooty mangabeys in West Africa. Nucleotide
sequence data suggest multiple sooty mangabey-
to-human transspecies transmissions (25).
Viable recombinants between SIV and HIV
(“SHIV” strains) have been genetically engineered
in research laboratories for use in animal
modeling experiments (26). No naturally occurring
HIV-1/HIV-2 recombinants have been detected in
human populations, but efforts to detect such
strains have been very limited. Although SIV
strains can productively infect humans and,
therefore, might recombine with HIV-1, the
lentiviruses of cats, horses, cows, and sheep
have not productively infected humans and are
unlikely to contribute to the pool of human
lentivirus genetic elements.
Barriers to HIV Recombination
Not all the theoretically possible combinations
between HIV-1, HIV-2, and SIVs may give rise to
recombinants in nature because of epidemiologic
and biologic barriers.
Segregation by Host Species
The frequency of transmission of viruses
between primate species is not known. Intense
surveillance for pox virus infections in equatorial
Africa during the final decade of the smallpox
eradication effort detected only 400 human mon-
keypox cases (27). Worldwide surveillance for
herpes B virus infection, a common infection in
nonhuman primates that is uniformly fatal in
humans, has identified only 40 cases.
Segregation by Geography
Although there are now perhaps 20 million
HIV-infected persons worldwide, few (except in
equatorial Africa) are likely to encounter part-
ners infected with another clade. This is because,
except in equatorial Africa, the HIV epidemic is
genetically relatively homogeneous: B clade
viruses predominate in Europe and North and
South America, C clade viruses predominate in
southern Africa and India, and E clade viruses
predominate in Southeast Asia (28,29).
The current geographic distribution of clades
and recombinants may not remain static. B clade
and F clade mixing has begun in South America,
and B/F recombinants have been detected. B
clade and C clade mixing is occurring in South
Africa, and E/A clade and C clade mixing is occur-
ring in Asia, but new interclade recombinants
have not yet been detected in these regions.
Requirement for Multiple Infections
in a Single Human
HIV-1 can superinfect persons who are
chronically infected with HIV-2, but there is
substantial heterotypic protection (30). Human
infections with two or more HIV-1 clades have
been recognized only rarely (31,32). While HIV-1-
infected chimpanzees can be superinfected with a
closely related strain under experimental condi-
tions (33), it is still unclear if chronically HIV-1-
infected humans are susceptible to superinfection
by another HIV-1 strain through natural trans-
mission. It may be that multiple infections with
HIV-1 can occur in humans only when exposure
to both viruses is near simultaneous.
Requirement for Dual Infection of a Single Cell
Different variant HIV-1 strains can concur-
rently infect single cells in cell cultures in vitro,
as can HIV-1 and HIV-2 (34). However, HIV
downregulates its CD4 cell surface receptor, and
dual infection of a single cell in vivo may require
simultaneous attachment and penetration.
Viral Structural Incompatibilities
The replication and synthesis of HIV virions
is a complex process with molecular interactions
at several levels: overlapping reading frames,
RNA/RNA secondary structures, protein/RNA
interactions, and intra- and intermolecular pro-
tein interactions. Recombination between two
highly replication competent parent viruses might
give rise to nothing but nonviable recombinant257 Vol. 3, No. 3, July–September 1997 Emerging Infectious Diseases
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progeny because of incompatibilities in these
molecular interactions.
Consequences of Recombination
for Prevention and Treatment
of HIV Infections
The propensity of HIV strains to recombine has
serious implications for epidemic control efforts.
Epidemic Forecasting
If new strains—with new epidemiologic
properties—can arise through HIV recombination
as readily as new strains arise through reas-
sortment in influenza A, then the long-term
epidemiology of HIV may similarly be charac-
terized by epidemic shifts and drifts. The
emergence of the E/A recombinant clade in
Southeast Asia may have simply been a chance
event. However the fact that the E/A clade has
spread much more rapidly than the B clade in
this region raises concerns that some recom-
binants may emerge through natural selection
based on their transmission efficiency (35).
Antiviral Drug Resistance
Most HIV strains that are highly resistant to
zidovudine (AZT) or to other antiviral drugs have
multiple mutations, which act synergistically to
confer the resistant phenotype to that drug. In
vitro experiments in which single-mutant strains
are grown in the presence of AZT show strong
selection for recombinants bearing two or more
resistance mutations (36). Multidrug resistant
HIV-1 strains are likely to arise in patients treated
with multiple drugs through recombination of
variants that are resistant to single drugs (37).
For example, crossover recombinants between
strains singly resistant to a nucleoside analog
and a protease inhibitor would be generated
frequently in any cell coinfected with variants
resistant to only one of these antiviral drugs.
Paradoxically, mutations in the reverse
transcriptase that confer drug resistance might
also serve to limit recombination. Mutations that
confer AZT resistance increase the processivity
of HIV-1 reverse transcription in vitro, but
recombination rates of viruses bearing these
mutations have not yet been studied (38).
Vaccines
If new HIV strains are continually generated
in nature through recombination, matching vac-
cines with prevalent genotypes in a particular
geographic region may prove difficult. This may
be less of a problem if small subunit vaccines are
effective but may be more serious if complex
vaccines constructed from antigens corresponding
to two or more HIV gene products are needed.
The need for a new influenza vaccine with each
shift in the dominant epidemic influenza strain
may be an instructive model. Another concern is
that HIV genetic information from a vaccine might
recombine with wild-type virus in vivo in an HIV-
infected patient who was vaccinated, giving rise
to new variants. Recombinant vaccinia strains
containing HIV genes have already been tested in
humans, and live attenuated and naked DNA
HIV vaccines are being considered (39). Although
in most instances it is unlikely that the new genetic
information from the vaccine could give rise to
more transmissible or more virulent strains, it is
nonetheless possible. A relevant example is a
recent epidemic in China, where gene sequences
from the live attenuated oral polio vaccine were
found to be stably recombined into the dominant
virulent wild-type virus (40).
Conclusion
Recombination may be an important fitness
search strategy in the ongoing evolution of HIV.
Many of the strains around the world appear to
have arisen through recombination, and it is
likely that recombination may be an important
mechanism by which HIV evades drug or immune
pressures. Future epidemiologic and clinical trials
should examine the role of recombination in HIV
evolution and adaptation, and computer models
that simulate HIV mutation and recombination
should be developed. The conceptual approach to
HIV replication as a primitive sexual reproductive
cycle might lead to new classes of interventions
that block HIV evolution and adaptation.
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